NLS Pharmaceutics Ltd. Files Form 6-K: December 2024 Report & Shareholder Meeting Details

Here are the key insights extracted from the provided section of the financial report:

1. Report Type and Filing Information:

• The document is a Form 6-K, which is a report of a foreign private issuer.
• It was filed with the SEC under the Securities Exchange Act of 1934.

2. Company Information:

• Company Name: NLS Pharmaceutics Ltd.
• Address: The Circle 6, 8058 Zurich, Switzerland.
• Commission File Number: 001-39957.

3. Reporting Period:

• The report is for the month of December 2024 and is identified as Report No. 4.

4. Shareholders' Meeting:

• An extraordinary shareholders' meeting is scheduled for January 7, 2025.
• Only shareholders of record as of December 16, 2024 (11:59 pm CET) are entitled to vote at the meeting.

5. Proxy Information:

• A Notice of Meeting and Proxy Card for the extraordinary shareholders' meeting has been attached and incorporated by reference in the report.

6. Incorporation by Reference:

• The report on Form 6-K will be incorporated by reference into the Registrant’s Registration Statements on Form F-3.

7. Signatures:

• The report was signed on December 17, 2024, by Alexander C. Zwyer, the Chief Executive Officer of NLS Pharmaceutics Ltd.

This report provides essential information about the upcoming shareholders' meeting, compliance with SEC regulations, and the company's administrative details.